These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 21937232)

  • 1. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
    Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L
    Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.
    Roché H; Conte P; Perez EA; Sparano JA; Xu B; Jassem J; Peck R; Kelleher T; Hortobagyi GN
    Breast Cancer Res Treat; 2011 Feb; 125(3):755-65. PubMed ID: 21128114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
    Fornier M
    Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
    J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Vahdat LT; Vrdoljak E; Gómez H; Li RK; Bosserman L; Sparano JA; Baselga J; Mukhopadhyay P; Valero V
    J Geriatr Oncol; 2013 Oct; 4(4):346-52. PubMed ID: 24472478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
    Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
    Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K
    Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
    Wang J; Fan Y; Xu B
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):597-603. PubMed ID: 20490795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
    Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN
    J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
    Corey-Lisle PK; Peck R; Mukhopadhyay P; Orsini L; Safikhani S; Bell JA; Hortobagyi G; Roche H; Conte P; Revicki DA
    Cancer; 2012 Jan; 118(2):461-8. PubMed ID: 21598243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
    Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
    Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Sparano JA; Vrdoljak E; Rixe O; Xu B; Manikhas A; Medina C; Da Costa SC; Ro J; Rubio G; Rondinon M; Perez Manga G; Peck R; Poulart V; Conte P
    J Clin Oncol; 2010 Jul; 28(20):3256-63. PubMed ID: 20530276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
    Lechleider RJ; Kaminskas E; Jiang X; Aziz R; Bullock J; Kasliwal R; Harapanhalli R; Pope S; Sridhara R; Leighton J; Booth B; Dagher R; Justice R; Pazdur R
    Clin Cancer Res; 2008 Jul; 14(14):4378-84. PubMed ID: 18628451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixabepilone, a new treatment option for metastatic breast cancer.
    Toppmeyer DL; Goodin S
    Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.